Anti-cancer-prostaglandin-induced cell-cycle arrest and its modulation by an inhibitor of the ATP-dependent glutathione S-conjugate export pump (GS-X pump). 1998

T Ishikawa, and K Akimaru, and M Nakanishi, and K Tomokiyo, and K Furuta, and M Suzuki, and R Noyori
Section of Molecular Therapeutics, Department of Experimental Pediatrics The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.

The A and J series of prostaglandins (PGs) accumulate in the nuclei to suppress the proliferation of cancer cells. Here we report that Delta7-PGA1 methyl ester, a synthetic anti-cancer PG, increased the level of mRNA for the cyclin-dependent kinase inhibitor p21 in human leukaemia HL-60 cells. The induction of p21 was associated with the accumulation of hypophosphorylated retinoblastoma protein (pRB) and the suppression of c-myc gene expression. Since the p53 gene is deleted in HL-60 cells, the anti-cancer PG is suggested to inhibit cancer cell growth by inducing p21 via a p53-independent pathway. Unlike HL-60 cells, cisplatin-resistant HL-60/R-CP cells were insensitive to Delta7-PGA1 methyl ester. While c-myc expression was transiently suppressed, neither G1 arrest nor hypophosphorylation of pRB was observed with the anti-cancer PG. Plasma membrane vesicles from HL-60/R-CP cells showed an enhanced level of GS-X pump (ATP-dependent glutathione S-conjugate export pump) activity towards the glutathione S-conjugate of Delta7-PGA1 methyl ester (Km 110 nM). GIF-0019 ¿N-carbomethoxy-S-[5-(4-benzoylphenyl)pentyl]glutathione dimethyl ester¿, a specific inhibitor of the GS-X pump, dose-dependently enhanced the cellular sensitivity of HL-60/R-CP cells to Delta7-PGA1 methyl ester and induced G1 arrest. The GS-X pump is suggested to play a pivotal role in modulating the biological action of the anti-cancer PG.

UI MeSH Term Description Entries
D011455 Prostaglandins A, Synthetic Analogs or derivatives of prostaglandin A that do not occur naturally in the body. They do not include the product of the chemical synthesis of hormonal PGA. PGA Synthetic,Prostaglandin A Analogs,Prostaglandin A Analogues,Synthetic Prostaglandins A,Analogs, Prostaglandin A,Analogues, Prostaglandin A,Synthetic, PGA
D002352 Carrier Proteins Proteins that bind or transport specific substances in the blood, within the cell, or across cell membranes. Binding Proteins,Carrier Protein,Transport Protein,Transport Proteins,Binding Protein,Protein, Carrier,Proteins, Carrier
D002453 Cell Cycle The complex series of phenomena, occurring between the end of one CELL DIVISION and the end of the next, by which cellular material is duplicated and then divided between two daughter cells. The cell cycle includes INTERPHASE, which includes G0 PHASE; G1 PHASE; S PHASE; and G2 PHASE, and CELL DIVISION PHASE. Cell Division Cycle,Cell Cycles,Cell Division Cycles,Cycle, Cell,Cycle, Cell Division,Cycles, Cell,Cycles, Cell Division,Division Cycle, Cell,Division Cycles, Cell
D002455 Cell Division The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION. M Phase,Cell Division Phase,Cell Divisions,Division Phase, Cell,Division, Cell,Divisions, Cell,M Phases,Phase, Cell Division,Phase, M,Phases, M
D002462 Cell Membrane The lipid- and protein-containing, selectively permeable membrane that surrounds the cytoplasm in prokaryotic and eukaryotic cells. Plasma Membrane,Cytoplasmic Membrane,Cell Membranes,Cytoplasmic Membranes,Membrane, Cell,Membrane, Cytoplasmic,Membrane, Plasma,Membranes, Cell,Membranes, Cytoplasmic,Membranes, Plasma,Plasma Membranes
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D006131 Growth Inhibitors Endogenous or exogenous substances which inhibit the normal growth of human and animal cells or micro-organisms, as distinguished from those affecting plant growth ( Cell Growth Inhibitor,Cell Growth Inhibitors,Growth Inhibitor,Growth Inhibitor, Cell,Growth Inhibitors, Cell,Inhibitor, Cell Growth,Inhibitor, Growth,Inhibitors, Cell Growth,Inhibitors, Growth
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000255 Adenosine Triphosphate An adenine nucleotide containing three phosphate groups esterified to the sugar moiety. In addition to its crucial roles in metabolism adenosine triphosphate is a neurotransmitter. ATP,Adenosine Triphosphate, Calcium Salt,Adenosine Triphosphate, Chromium Salt,Adenosine Triphosphate, Magnesium Salt,Adenosine Triphosphate, Manganese Salt,Adenylpyrophosphate,CaATP,CrATP,Manganese Adenosine Triphosphate,MgATP,MnATP,ATP-MgCl2,Adenosine Triphosphate, Chromium Ammonium Salt,Adenosine Triphosphate, Magnesium Chloride,Atriphos,Chromium Adenosine Triphosphate,Cr(H2O)4 ATP,Magnesium Adenosine Triphosphate,Striadyne,ATP MgCl2
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy

Related Publications

T Ishikawa, and K Akimaru, and M Nakanishi, and K Tomokiyo, and K Furuta, and M Suzuki, and R Noyori
November 1992, Trends in biochemical sciences,
T Ishikawa, and K Akimaru, and M Nakanishi, and K Tomokiyo, and K Furuta, and M Suzuki, and R Noyori
May 1997, Nihon rinsho. Japanese journal of clinical medicine,
T Ishikawa, and K Akimaru, and M Nakanishi, and K Tomokiyo, and K Furuta, and M Suzuki, and R Noyori
September 1998, Biochemistry and molecular biology international,
T Ishikawa, and K Akimaru, and M Nakanishi, and K Tomokiyo, and K Furuta, and M Suzuki, and R Noyori
September 1998, Biochemistry and molecular biology international,
T Ishikawa, and K Akimaru, and M Nakanishi, and K Tomokiyo, and K Furuta, and M Suzuki, and R Noyori
March 1996, The Biochemical journal,
T Ishikawa, and K Akimaru, and M Nakanishi, and K Tomokiyo, and K Furuta, and M Suzuki, and R Noyori
November 1995, Biochemical and biophysical research communications,
T Ishikawa, and K Akimaru, and M Nakanishi, and K Tomokiyo, and K Furuta, and M Suzuki, and R Noyori
June 1997, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme,
T Ishikawa, and K Akimaru, and M Nakanishi, and K Tomokiyo, and K Furuta, and M Suzuki, and R Noyori
April 2004, Biochemical pharmacology,
T Ishikawa, and K Akimaru, and M Nakanishi, and K Tomokiyo, and K Furuta, and M Suzuki, and R Noyori
October 1996, European journal of biochemistry,
T Ishikawa, and K Akimaru, and M Nakanishi, and K Tomokiyo, and K Furuta, and M Suzuki, and R Noyori
February 1995, The Journal of biological chemistry,
Copied contents to your clipboard!